Literature DB >> 15990761

A propensity score analysis of the impact of angiotensin-converting enzyme inhibitors on long-term survival of older adults with heart failure and perceived contraindications.

Ali Ahmed1, Robert M Centor, Michael T Weaver, Gilbert J Perry.   

Abstract

OBJECTIVES: The purpose of this study is to determine the association between discharge use of angiotensin-converting enzyme (ACE) inhibitors in patients with perceived contraindications to these drugs and 4-year post-discharge survival among hospitalized older adults discharged alive with a primary discharge diagnosis of systolic heart failure.
BACKGROUND: Perceived contraindications to the use of ACE inhibitors are often associated with underuse of these life-saving drugs.
METHODS: Chronic renal insufficiency, hypotension, hyperkalemia, and severe aortic stenosis were conditions perceived as contraindications. Using a multivariable logistic regression model, we at first determined propensity scores for receipt of ACE inhibitors for each patient. Bivariate and multivariable Cox proportional hazard analyses were used to determine crude and adjusted risks of 4-year mortality compared with patients without perceived contraindications who were discharged on an ACE inhibitor (referent group).
RESULTS: Compared with the referent group, patients with perceived contraindications who were not discharged on an ACE inhibitor had a significant 2-fold increase in the risk of 4-year mortality (adjusted hazard ratio [HR] = 2.33, 95% CI = 1.30-4.19). Patients with perceived contraindications who were discharged on ACE inhibitors had a non significant 23% higher risk of 4-year mortality (versus the referent group) (adjusted HR = 1.23, 95% CI = 0.71-2.13).
CONCLUSION: Discharge use of ACE inhibitors was associated with significant long-term survival benefit in patients considered to have contraindication to these drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15990761     DOI: 10.1016/j.ahj.2004.06.030

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  14 in total

Review 1.  Systolic heart failure in the elderly: optimizing medical management.

Authors:  Jonathan P Man; Bodh I Jugdutt
Journal:  Heart Fail Rev       Date:  2012-09       Impact factor: 4.214

Review 2.  Emerging medical treatments for aortic stenosis: statins, angiotensin converting enzyme inhibitors, or both?

Authors:  D E Newby; S J Cowell; N A Boon
Journal:  Heart       Date:  2006-06       Impact factor: 5.994

3.  Causes and impact on survival of underuse of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in heart failure.

Authors:  Edoardo Bertero; Roberta Miceli; Alessandra Lorenzoni; Manrico Balbi; Giorgio Ghigliotti; Francesco Chiarella; Claudio Brunelli; Francesca Viazzi; Roberto Pontremoli; Marco Canepa; Pietro Ameri
Journal:  Intern Emerg Med       Date:  2019-03-05       Impact factor: 3.397

Review 4.  Heart Failure in Older Adults.

Authors:  Hoda Butrous; Scott L Hummel
Journal:  Can J Cardiol       Date:  2016-05-10       Impact factor: 5.223

5.  Effects of angiotensin-converting enzyme inhibitors in systolic heart failure patients with chronic kidney disease: a propensity score analysis.

Authors:  Ali Ahmed; Thomas E Love; Xuemei Sui; Michael W Rich
Journal:  J Card Fail       Date:  2006-09       Impact factor: 5.712

6.  Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD Treatment trial.

Authors:  C Barrett Bowling; Paul W Sanders; Richard M Allman; William J Rogers; Kanan Patel; Inmaculada B Aban; Michael W Rich; Bertram Pitt; Michel White; George C Bakris; Gregg C Fonarow; Ali Ahmed
Journal:  Int J Cardiol       Date:  2012-01-17       Impact factor: 4.164

7.  Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease.

Authors:  Ali Ahmed; Gregg C Fonarow; Yan Zhang; Paul W Sanders; Richard M Allman; Donna K Arnett; Margaret A Feller; Thomas E Love; Inmaculada B Aban; Raynald Levesque; O James Ekundayo; Louis J Dell'Italia; George L Bakris; Michael W Rich
Journal:  Am J Med       Date:  2012-02-07       Impact factor: 4.965

8.  Outcomes in ambulatory chronic systolic and diastolic heart failure: a propensity score analysis.

Authors:  Ali Ahmed; Gilbert J Perry; Jerome L Fleg; Thomas E Love; David C Goff; Dalane W Kitzman
Journal:  Am Heart J       Date:  2006-11       Impact factor: 4.749

9.  Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease.

Authors:  Miklos Z Molnar; Kamyar Kalantar-Zadeh; Evan H Lott; Jun Ling Lu; Sandra M Malakauskas; Jennie Z Ma; Darryl L Quarles; Csaba P Kovesdy
Journal:  J Am Coll Cardiol       Date:  2013-11-21       Impact factor: 24.094

10.  Registry in Germany focusing on level-specific and evidence-based decision finding in the treatment of heart failure: REFLECT-HF.

Authors:  Ulrich Tebbe; Carsten Tschöpe; Jost Henner Wirtz; Jan Lokies; Eva Turgonyi; Peter Bramlage; Anke M Strunz; Katharina Lins; Michael Böhm
Journal:  Clin Res Cardiol       Date:  2014-02-18       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.